Pattern illustration of DNA helix fish with a pink background for the CytoCell FISH product range.

Hematology FISH probes for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)

AML and MDS are neoplastic hematological disorders that arise from myeloid progenitor cells in the bone marrow. AML is characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow or other tissues, while MDS is characterized by the simultaneous proliferation and apoptosis of hemopoietic cells1.

According to the World Health Organization (WHO), the global incidence for MDS is 3-5 cases per 100,000 (non-age corrected) with approximately 10,000 new cases of MDS diagnosed annually in the USA1. The Surveillance Epidemiology and End Results (SEER) statistics present a similar picture for AML with a USA incidence of 4.3 per 100,000 (non-sex specific)2.

Our range of CytoCell® FDA-cleared Class II IVD FISH probe test kits have been specifically designed to detect common chromosomal rearrangements reported in AML and MDS.

  • Reduce the validation burden for your laboratory: proven safe and effective probes
  • Ensure optimal FISH test performance: FISH probe, DAPI, detailed protocol and analysis guidelines
  • Reduce retest rates: high-intensity signals with excellent contrast 
  • Simplify processing and minimize chance for error: easy-to-use, pre-mixed probes 
Watch the recommended protocol for our CytoCell FDA-cleared hematology FISH probes for AML and MDS

Request an evaluation
of our FDA-cleared
FISH probes

Discover our FISH probes for AML and MDS

AML1/ETO Translocation, Dual Fusion

View

CBFß/MYH11 Translocation, Dual Fusion

View

Del(5q) Deletion

View

Del(7q) Deletion

View

Del(20q) Deletion

View

EVI1 (MECOM) Breakapart

View

MLL (KMT2A) Breakapart

View

P53 (TP53) Deletion

View

Featured resources for our CytoCell FDA-cleared probes

References

  1. Swerdlow, et al (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, Lyon, France, 4th edition, IARC,2017.
  2. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.

Disclaimer

CytoCell®: For In Vitro Diagnostic Use. Rx only. This product has not been validated for use on sample types other than bone marrow specimens, and has not been validated on disease types other than AML or MDS. The CytoCell AML/MDS range of FISH probe test kits are fluorescence in situ hybridization (FISH) tests used to detect common chromosomal rearrangements in fixed bone marrow specimens from patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The tests are indicated for the characterization of patient specimens consistent with World Health Organization guidelines for Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th Edition) and in conjunction with other clinicopathological criteria. The assay results are to be interpreted by a qualified pathologist or cytogeneticist. The tests are not intended for use as a stand-alone diagnostic, disease screening, or as a companion diagnostic.

Refer to individual test kit Package Insert for the specific intended use and limitations.

The CytoCell AML/MDS range of FISH probe test kits are for sale in the US only. These products have not been licensed in accordance with Canadian law.

Have a question or want to know more about our CytoCell FISH products?

Call +44 (0)1865 856800 Email contact@ogt.com Send us a message and we will get back to you
Contact our FISH experts